Exicure, Inc. (XCUR)
NASDAQ: XCUR · Real-Time Price · USD
18.67
+2.93 (18.62%)
Dec 20, 2024, 4:00 PM EST - Market closed
Company Description
Exicure, Inc. does not have significant operations.
previously, the company focused on developing of nucleic acid therapies targeting ribonucleic acid against validated targets.
Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.
Exicure, Inc.
| Country | United States |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Paul Kang |
Contact Details
Address: 2430 North Halsted Street Chicago, Illinois 60614 United States | |
| Phone | 847 673 1700 |
| Website | exicuretx.com |
Stock Details
| Ticker Symbol | XCUR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001698530 |
| CUSIP Number | 30205M101 |
| ISIN Number | US30205M2008 |
| Employer ID | 81-5333008 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Paul Kang | Chief Executive Officer, President and Director |
| Jiyoung Hwang | Chief Financial Officer, Secretary and Director |
| Joshua Miller | Chief Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 20, 2024 | 8-K | Current Report |
| Dec 17, 2024 | 8-K | Current Report |
| Dec 11, 2024 | 8-K | Current Report |
| Dec 2, 2024 | DEF 14A | Other definitive proxy statements |
| Nov 29, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Nov 25, 2024 | 8-K | Current Report |
| Nov 22, 2024 | PRE 14A | Other preliminary proxy statements |
| Nov 20, 2024 | 8-K | Current Report |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 14, 2024 | 8-K | Current Report |